Substituted pyrazoles as LRRK2 inhibitors

A compound of Formula 1:

• or a pharmaceutically acceptable salt or stereoisomer thereof,
• wherein:
• X is CH or N;
• R1 is hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, OC1-4 alkyl, or OC1-4 haloalkyl;
• R2 is C1-6 alkyl, C1-6 alkylene-OC1-3 alkyl, C1-6 alkylene-C3-6 cycloalkyl, OC1-6 alkyl, C3-6 cycloalkyl, 4- to 7-membered heterocycloalkyl, or C6-10 aryl;
• wherein the 4- to 7-membered heterocycloalkyl contains one or more heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
• wherein the 4- to 7-membered heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of C1-4 alkyl, C(O)C1-4 alkyl, C(O)C1-4 haloalkyl, C(O)C3-6 cycloalkyl, C(O)-(4- to 7-membered heterocycloalkyl), S(O)2C1-4 alkyl, S(O)2C3-6 cycloalkyl, and oxetanyl;
• wherein each 4- to 7-membered heterocycloalkyl of each C(O)-(4- to 7-membered heterocycloalkyl) substituent of the 4- to 7-membered heterocycloalkyl is optionally substituted with one or more independently selected C1-4 alkyl substituents;
• and
• wherein the C6-10 aryl is optionally substituted with one or more independently selected halogen substituents;
• R3 is hydrogen, halogen, or C1-4 alkyl;
• R4 is C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl;
• wherein the C3-6 cycloalkyl is optionally substituted with one or more independently selected halogen substituents;
• and
• R5 is halogen, C1-4 alkyl, or C1-4 haloalkyl.